The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://poppyickn959474.wikikali.com/1844927/retatrutide_vs_tirzepatide_a_comparative_analysis